"Highlands Oncology is dedicated to providing the highest quality of innovative cancer care delivered with compassion and precision. With locations in Springdale, Fayetteville, and Rogers, we provide Northwest Arkansas with comprehensive cancer care."

During the past decade, Highlands Oncology Group - Springdale conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 3 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 1 clinical trials were completed. i.e. 14.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Highlands Oncology Group - Springdale" #1 sponsor was "SWOG Cancer Research Network" with 4 trials, followed by "CTI BioPharma" with 2 trials sponsored, "Alliance for Clinical Trials in Oncology" with 1 trials sponsored, "Ascentage Pharma Group Inc." with 1 trials sponsored and "Calico Life Sciences LLC" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Highlands Oncology Group - Springdale" #1 collaborator was "National Cancer Institute (NCI)" with 7 trials as a collaborator, "Cancer and Leukemia Group B" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "BeiGene" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Highlands Oncology Group - Springdale" are "Endometrial Cancer" (2 trials), "Lung Cancer" (2 trials), "Pancreatic Cancer" (2 trials), "Prostate Cancer" (2 trials) and "Advanced Solid Tumors Cancer" (1 trials). Many other conditions were trialed in "Highlands Oncology Group - Springdale" in a lesser frequency.

Most popular intervention types in "Highlands Oncology Group - Springdale" are "Drug" (14 trials), "Biological" (4 trials), "Other" (1 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "ABBV-CLS-579" (1 trials), "APG-5918" (1 trials), "Aspirin" (1 trials), "Atezolizumab" (1 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Highlands Oncology Group - Springdale" are 13 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Highlands Oncology Group - Springdale". undefined are not yet recruiting, 6 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Highlands Oncology Group - Springdale, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Highlands Oncology Group - Springdale, 3 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".